BioSpace News Archive

Invacare Corporation reported results for the quarter ended September 30, 2022.

Day One Biopharmaceuticals announced financial results for the third quarter of 2022 and highlighted recent corporate achievements.

Marinus Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 2,105,264 shares of common stock at a price of $4.749 per pre-funded warrant, for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and offering expenses payable by Marinus.

GreenLight Biosciences announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.

PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced that the organization’s recent research will be presented at the Society for Immunotherapy of Cancer’s 37th annual meeting (SITC), which will be held in Boston, MA from November 8-12, 2022.

ValnevaSE announced that its Chief Executive Officer Thomas Lingelbach and Chief Financial Officer Peter Bühler will present and participate in 1-on-1 meetings with institutional investors at the Jefferies London Healthcare Conference, to take place November 15-17, 2022 in London, England.

POXEL SA announced its participation at the Jefferies London Healthcare Conference, to be held in London from Tuesday, November 15 to Thursday, November 17, 2022.

Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins.

Insightec announced the publication of the largest prospective, long-term follow-up study of unilateral MRI-guided focused ultrasound thalamotomy for essential tremor to date.

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the company’s scientific and management team’s participation in several scientific and investor conferences in November.